HGS says US approval of fortnightly Zalbin is unlikely
This article was originally published in Scrip
Executive Summary
Human Genome Sciences has said that the US FDA is unlikely to approve the BLA for a fortnightly 900µg dosing regimen of its hepatitis C candidate Zalbin (albinterferon alfa-2b; known as Joulferon in Europe).